Younis A, Goldberger JJ, Kutyifa V, et al. - Given that disparities in the risk of life-threatening ventricular tachycardia (VT)/ventricular fibrillation (VF) and non-arrhythmic mortality are responsible for non-uniform benefit of prophylactic implantable cardioverter-defibrillator (ICD), researchers sought to construct an ICD benefit prediction score that combines the competing risks. Participants were 4,531 patients enrolled in the MADIT (Multicenter Automatic Defibrillator Implantation) trials. Experts found 8 predictors of VT/VF and 7 predictors of non-arrhythmic death. Three MADIT-ICD benefit groups were defined by combining the two scores: the highest benefit group; the intermediate benefit group; and the lowest benefit group. Experts created a personalized ICD benefit score on the basis of distribution of the two competing risks scores in the study population (https://is.gd/madit). Model stability was corroborated by internal and external validation. Overall, the probability of preventive ICD benefit can be predicted with the help of the novel MADIT-ICD benefit score proposed herein that allows personalized evaluation of the risk of VT/VF weighed against the risk of non-arrhythmic mortality.